Evaluation of a one-year pilot utilizing extended-release buprenorphine (XRB) for the treatment of opioid use disorder in a rural jail found that, when compared to those receiving sublingual buprenorphine, persons receiving XRB were almost three times as likely to receive timely community OUD treatment postrelease. Learn how utilization of XRB allowed for expanded access to OUD treatment, was well tolerated, and reduced medication diversion.

Level: Intermediate